¥t¥~¡A°·«O¸p»¡©ú¡A¥»¦¸·|ij¥ç¦P·N¨ä¥L¦hºØ·s¦¨¤À·sÃįǤJ°·«Oµ¹¥I¡AºKz¦p¤U¡G
1.ªvÀø¡u°ª·ÀI«DÂಾ©Ê¥h¶Õ§Ü©Ê«e¦C¸¢Àù(nmCRPC)¡v¤Î¡uÂಾ©Ê¥h¶Õ±Ó·P©Ê«e¦C¸¢Àù(mCSPC)¡v¤§§tapalutamide·s¦¨¤À·sÃÄ¡A¹ï©ó¡uÂಾ©Ê¥h¶Õ±Ó·P©Ê«e¦C¸¢Àù(mCSPC)¡v¤§ªvÀø¬°·sÃIJz¾÷Âध¥ÎÃÄ¡C
2.ªvÀø¦¸µo®i«¬¦hµo©Êµw¤Æ¯g¤§§tsiponimod·s¦¨¤À·sÃÄ¡A¬°¤fªA¾¯«¬¥i´£¤É¯f¤H¨Ï¥ÎªvÀø¤§¤è«K©Ê¡C
3.¥Î©ó¹w¨¾¦¨¤H°¾ÀYµh¤§§tgalcanezumab·s¦¨¤À·sÃÄ¡A¬°·sªºªvÀø¾÷Âà¡C
4.ªvÀø«I¥Ç©ÊÄTµß¯g¤Î¥ÕÅðµß¯g¤§§tisavuconazole·s¦¨¤À·sÃÄ¡A¯S§O¬O¦bªvÀøÄTµß·P¬V¤è±¡A¦b¨xŦ¡B²´·ú¡B¥Ö½§¤Î¥Ö¤U²Õ´¤§°Æ§@¥Î¸û²{¦³ªvÀøÃÄ«~¤p¡C
5.¹ï©ó§ÜÃĩʺñÁw±ìµß¤Î§ÜÃĩʤj¸z±ìµß¨ãÀø®Ä¤§§tceftolozane/tazobacctam¦¨¤À§Üµß¾¯¡A¥i´î¤ÖcarbapenemsÃþ§Ü¥Í¯À¨Ï¥Î¡A¶i¦Ó¥i¯à´î½w§Ü¥Í¯À§ÜÃĩʪº´²¥¬¡A¹ï©ó§ÜÃĩʲӵߤ§ªvÀø¨ãÁ{§É«n©Ê¡C
6.ªvÀøÀù¦]©Ê¯h¾Î¯g¤§§tpolysaccharides of astragalus membranaceus·s¦¨¤À·sÃÄ¡A¦b»OÆW¬°°ê»Ú¶¡²Ä¤@Ó¤W¥«¡A¹wp¨C¦~¬ù¦³500¦h¦W¯f±w¨ü´f¡C
¥»¤å¸g °·±dÂåÀøºô ±ÂÅv¥Zµn¡Aì¤åµoªí
©ó¦¹
¡i°·±dÂåÀøºô¡þ°OªÌªL©É«F³ø¾É¡j2021/02/05